Financing co-led by ARCH Venture Partners and GV (Google Ventures) to support continued advancement of PP405, a topical therapy designed to reactivate dormant hair follicle stem cells to restore hair growth
Positive Phase 2a results in androgenetic alopecia support progression into Phase 3 trials in 2026
Cathy Friedman of GV has been appointed Chair of the Board; Richard Heyman of ARCH Venture Partners joins the Board of Directors
Inclusive trial recruiting women and men with androgenetic alopecia to evaluate safety and preliminary efficacy of PP405, a topical treatment designed to reactivate dormant hair follicle stem cells
$14M financing led by GV (Google Ventures) to accelerate Phase 2 clinical program
Leaders in dermatology join Clinical Advisory Board (CAB) to advance clinical development
Pioneers novel approach to restore the body’s natural ability to grow hair by reactivating dormant hair follicle stem cells
Phase I clinical data meets primary safety endpoints and shows statistically significant stem cell activation in hair follicles after one week of treatment with PP405; Phase 2 clinical trial to begin in mid-2024
Announces the appointment of Qing Yu Christina Weng, M.D., as Chief Medical Officer
